Algorithm Matches Pediatric Patients with Cancer to Precision Medicines
May 29th 2020Utilizing data from the INFORM registry, researchers were able to identify high level priority targets in pediatric patients with cancer utilizing an algorithm that matched them to targeted treatments extending their progression-free survival time and showing the feasibility of this program in a real-world setting.
Study Finds No Benefit to Surgery, Radiation in De Novo Stage IV Breast Cancer
May 29th 2020Women who present with a new diagnosis of breast cancer already in stage IV should not be offered surgery and radiation for the primary breast tumor with the expectation of a survival benefit, according to results from the ECOG-ACRIN E2108 trial.
Cancer Progression Linked to Increased Risk of Death Within 30 Days of COVID-19 Diagnosis
May 28th 2020Disease progression and treatment with hydroxychloroquine and azithromycin were associated with increased all-cause 30-day mortality in patients with cancer compared to patients either in remission or with no evidence of disease, according to data presented during a 2020 ASCO Virtual Scientific Program press briefing.
Dr. Adi Diab on Baseline Tumor Immune Signatures and Therapy Response in Solid Tumors
June 20th 2019Cancer Network spoke with Adi Diab, MD, of MD Anderson Cancer Center, on the link between baseline tumor immune signatures and response to bempegaldesleukin and nivolumab in patients with advanced solid tumors.
Dr. Anna Pavlick on Dendritic Cells vs Montanide in Melanoma Patients in Remission
June 20th 2019Cancer Network spoke with Anna Pavlick, MD, of NYU Langone Health, on the results of a phase II study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared with Montanide.
Dr. Hussein Tawbi on Efficacy and Safety Results From the CheckMate 204 Melanoma Trial
June 19th 2019Cancer Network spoke with Hussein Tawbi, MD, PhD, of MD Anderson Cancer Center, about the efficacy and safety of the combination of nivolumab plus ipilimumab in patients with symptomatic melanoma brain metastases.